News | October 28, 2021
Indian Pharma Market witnesses rise in volumes and prices in September.
Acute therapies continue to report strong growth compared to chronic ones.
Acute therapies continue to report strong growth compared to chronic ones.
It is the first company to launch Remogliflozin, Vildagliptin and Metformin combination
The company claims that its Empagliflozin tablets are the most affordable in India
BDMP is a personalised program delivered through the Breathe app to assist people with Type 2 Diabetics to achieve healthy outcomes
The company plans to expand its portfolio in regulated markets aggressively
Droxidopa capsules, 100 mg, 200 mg, and 300 mg is a generic equivalent of Northera capsules, 100 mg, 200 mg, and 300 mg, of Lundbeck NA
Post normalisation of high growth months of April and May this year the average IPM growth from June to August this year stood at 15.2 % YoY : Ind-Ra reports
The two startups will utilise the capital for business growth including strategic expansion, product development, R&D and technology investments
The consultations are virtual and they have launched the Diabetes Reversal Programme to address the issue
Between 30-40 per cent of Covid-19 patients are either obese or diabetic
Subscribe To Our Newsletter & Stay Updated
